Virios Therapeutics is a development-stage biotechnology company, which engages in the improvement of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. Co.'s primary candidate, IMC-1, is a proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. The VIRI average annual return since 2020 is shown above.
The Average Annual Return on the VIRI average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VIRI average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VIRI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|